Hypothyroidism results in small dense LDL independent of IRS traits and hypertriglyceridemia

Endocrine Journal

Volumn 55, Issue 2, 2008, Pages 381-389

  Abbas, Jasem M K ^a   Chakraborty, Jagadish ^b   Akanji, Abayomi O ^b   Doi, Suhail A R ^a,c  

^a MUBARAK AL KABEER HOSPITAL   (Kuwait)

^b KUWAIT UNIVERSITY   (Kuwait)

^c Kuwait Foundation for the Advancement of Science   (Kuwait)

Author keywords

Atherosclerosis; Hypothyroidism; Small dense LDL

Indexed keywords

LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PARTICLE SIZE; PHENOTYPE; TRIACYLGLYCEROL BLOOD LEVEL; UNIVARIATE ANALYSIS;

ADULT; APOLIPOPROTEINS B; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; INSULIN RESISTANCE; LIPOPROTEINS, LDL; LOGISTIC MODELS; MALE; MIDDLE AGED; PARTICLE SIZE; RISK FACTORS; THYROID GLAND;

EID: 43449091942     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K07E-065     Document Type: Article

References (40)

1. Anonymous (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285: 2486-2497.
2. Rizzo M, Berneis K (2006) Low-density lipoprotein size and cardiovascular risk assessment. QJM 99: 1-14.
3. Sacks FM, Campos H (2003) Clinical review 163: Cardiovascular endocrinology: Low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab 88: 4525-4532.
4. Berneis KK, Krauss RM (2002) Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 43: 1363-1379.
5. Kwon SW, Yoon SJ, Kang TS, Kwon HM, Kim JH, Rhee J, et al. (2006) Significance of small dense low-density lipoprotein as a risk factor for coronary artery disease and acute coronary syndrome. Yonsei Med J 47: 405-414.
6. Rizzo M, Berneis K, Corrado E, Novo S (2006) The significance of low-density-lipoproteins size in vascular diseases. Int Angiol 25: 4-9.
7. Roscini AR, Lupattelli G, Siepi D, Pagliaricci S, Pirro M, Mannarino E (1999) Low-density lipoprotein size in primary hypothyroidism. Effects of hormone replacement therapy. Ann Nutr Metab 43: 374-379.
8. Ozcan O, Cakir E, Yaman H, Akgul EO, Erturk K, Beyhan Z, et al. (2005) The effects of thyroxine replacement on the levels of serum asymmetric dimethylarginine (ADMA) and other biochemical cardiovascular risk markers in patients with subclinical hypothyroidism. Clin Endocrinol (Oxf) 63: 203-206.
9. Hirano T, Ito Y, Yoshino G (2005) Measurement of small dense low-density lipoprotein particles. J Atheroscler Thromb 12: 67-72.
10. Hoefner DM, Hodel SD, O'Brien JF, Branum EL, Sun D, Meissner I, et al. (2001) Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem 47: 266-274.
11. Hirany SV, Othman Y, Kutscher P, Rainwater DL, Jialal I, Devaraj S (2003) Comparison of low-density lipoprotein size by polyacrylamide tube gel electrophoresis and polyacrylamide gradient gel electrophoresis. Am J Clin Pathol 119: 439-445.
12. Ensign W, Hill N, Heward CB (2006) Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics. Clin Chem 52: 1722-1727.
13. Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD (2005) Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Small, Dense LDL Particles in Human Plasma. Clin Chem 51: 2264-2273.
14. Kazumi T, Kawaguchi A, Hozumi T, Nagao M, Iwahashi M, Hayakawa M, et al. (1999) Low density lipoprotein particle diameter in young, nonobese, normolipidemic Japanese men. Atherosclerosis 142: 113-119.
15. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC (2000) Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med 132: 270-278.
16. Walsh JP, Bremner AP, Bulsara MK, O'Leary P, Leedman PJ, Feddema P, et al. (2005) Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med 165: 2467-2472.
17. Imaizumi M, Akahoshi M, Ichimaru S, Nakashima E, Hida A, Soda M, et al. (2004) Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism. J Clin Endocrinol Metab 89: 3365-3370.
18. Klein I (1990) Thyroid hormone and the cardiovascular system. Am J Med 88: 631-637.
19. Klein I, Ojamaa K (2001) Thyroid hormone and the cardiovascular system. N Engl J Med 344: 501-509.
20. Bengel FM, Nekolla SG, Ibrahim T, Weniger C, Ziegler SI, Schwaiger M (2000) Effect of thyroid hormones on cardiac function, geometry, and oxidative metabolism assessed noninvasively by positron emission tomography and magnetic resonance imaging. J Clin Endocrinol Metab 85: 1822-1827.
21. Lekakis J, Papamichael C, Alevizaki M, Piperingos G, Marafelia P, Mantzos J, et al. (1997) Flow-mediated, endothelium-dependent vasodilation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high-normal serum thyrotropin (TSH) values. Thyroid 7: 411-414.
22. Hamano K, Inoue M (2005) Increased risk for atherosclerosis estimated by pulse wave velocity in hypothyroidism and its reversal with appropriate thyroxine treatment. Endocr J 52: 95-101.
23. Dagre AG, Lekakis JP, Papaioannou TG, Papamichael CM, Koutras DA, Stamatelopoulos SF, et al. (2005) Arterial stiffness is increased in subjects with hypothyroidism. Int J Cardiol 103: 1-6.
24. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, et al. (1997) Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 95: 69-75.
25. St-Pierre AC, Cantin B, Dagenais GR, Mauriege P, Bernard PM, Despres JP, et al. (2005) Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 25: 553-559.
26. Austin MA, Jarvik GP, Hokanson JE, Edwards K (1993) Complex segregation analysis of LDL peak particle diameter. Genet Epidemiol 10: 599-604.
27. Tribble DL, Rizzo M, Chait A, Lewis DM, Blanche PJ, Krauss RM (2001) Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. Am J Med 110: 103-110.
28. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM (1988) Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260: 1917-1921.
29. Selby JV, Austin MA, Newman B, Zhang D, Quesenberry CP Jr, Mayer EJ, et al. (1993) LDL subclass phenotypes and the insulin resistance syndrome in women. Circulation 88: 381-387.
30. Austin MA, King MC, Vranizan KM, Krauss RM (1990) Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 82: 495-506.
31. Sniderman AD, Rosenbloom M (2005) If apoB is so good, why isn't everybody measuring it? One reason why we need The Netherlands Journal of Medicine! Neth J Med 63: 232-235.
32. Guerin M, Le Goff W, Lassel TS, Van Tol A, Steiner G, Chapman MJ (2001) Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes : impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol 21: 282-288.
33. Jansen H, Verhoeven AJ, Sijbrands EJ. Hepatic lipase: a pro- or anti-atherogenic protein? J Lipid Res 2002; 43: 1352-1362.
34. Ikewaki K, Noma K, Tohyama J, Kido T, Mochizuki S (2005) Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia - a nuclear magnetic resonance study. Int J Cardiol 101: 441-447.
35. Superko HR, Berneis KK, Williams PT, Rizzo M, Wood PD (2005) Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A. Am J Cardiol 96: 1266-1272.
36. Elisaf M (2002) Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 18: 269-276.
37. Jonkers IJ, Smelt AH, van der Laarse A (2001). Hypertriglyceridemia: associated risks and effect of drug treatment. Am J Cardiovasc Drugs 1: 455-466.
38. Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, et al. (2003) Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 361: 777-780.
39. Jialal I, Devaraj S, Venugopal SK (2004) C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 44: 6-11.
40. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347: 1557-1565.